Xiamen Biotime Biotechnology
Xiamen Biotime Biotechnology Co., Ltd. is a high-tech enterprise specialized in the development, production, and sales of POCT in vitro diagnostic reagents. It has a scientific research team which is led by a doctor with foreign education background and is composed of dozens of master and doctoral talents. The company is lead by a senior management team which is composed of experienced talents from various fields with over 20 years of industry experience.
At present, the total number of employees in the company is more than 6000. In just a few years, the company's performance has doubled year by year. In 2017, the company made a leap in enlarging its annual production scale above the standard from its below. In 2018, it was rated as one of the top 20 enterprises with the most comprehensive strength in China's POCT industry. Biotime has been recognized by more than 20 achievement awards, such as National High-tech Enterprise, Leading New R&D Institution, Small Giant in Science and Technology, High-growth Enterprise in the Field of Industry and Information Technology, Small and Medium-sized Enterprise "with Specialization, Refinement, Characteristic and Novelty,” and Xiamen City Health Brand Enterprise. It has obtained capital assistance and completed the pre-A round of financing of RMB 30 million yuan.
The company focuses on the research of POCT precision medical rapid diagnosis technology. The technology platform covers colloidal gold, fluorescence immunochromatography, high-performance liquid chromatography, mass spectrometry, electrochemistry, light-induced chemiluminescence, coagulation, Raman, molecular POCT, and other precision diagnosis technologies.
Over the past years, it has obtained over 50 core independent intellectual property rights and developed more than 60 rapid diagnostic reagents and other instruments for maternal and infant health, inflammation, hormone, cardiac muscle, thyroid function, tumor series etc.
All of these have qualified for the registration certificates for medical devices. Among them, 10 products such as progesterone are the first of their kind in China, and more than 35 products have obtained CE certification. In addition, Biotime takes Northwest University as the scientific research practice base and has carried out long-term cooperation and innovation with Sandford-Burham Medical Research Institute, Xiamen University, Third Institute of Oceanography, MNR, all of which are industry and national-level research institutions. At the same time, Biotime committed to the integration of the upstream and downstream of industrial chains and independently sets up a raw material development platform, which can monitor the source of core raw materials for the diagnostic reagents to ensure the stability of materials, improve product quality and continuously enhance the market competitiveness.
With the worldwide outbreak of COVID-19 in 2020, the company has responded rapidly and independently developed a number of virus detection kits, which have been approved by FDA EUA, CE, MHRA and countries such as Russia, Brazil, Ukraine, Philippines, Thailand, Ecuador to name a few.
Besides, Xiamen Biotime Biotechnology conducts performance verification in foreign authoritative institutions and has obtained brilliant evaluation results from Barts Health in UK, Amiens University Medical Center in France, HUSLAB Diagnostic Center in Finland. The products have been worldwide to help with the fight against the COVID-19 epidemic with their excellent quality. In addition, Biotime has a strong ability to integrate the resources of supply chain and a strict system to control product quality. Biotime daily production capacity has been rapidly increased by hundreds times in just few months relying on the colloidal gold platform developed by the COVID-19 products, which has formed a Chinese manufacturing base effect, and Biotime will embark on a dual-track development way of independent brand and OEM production in the near future.